New York, NY, USA, 02/15/2018 /SubmitPressRelease123/
TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced today it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs.
TGV Therapeutics and its advisors, Dr.
News Source: http://www.WiredPRNews.com
